HRES 1285 · Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Referred to the House Committee on Energy and Commerce.
- Introduced
- May 14, 2026
- Latest action
- May 14, 2026
- Sponsor
- Rep. Diana DeGette [D-CO-1]
- Policy area
- Unassigned
- Cosponsors
- 42
Recent actions
- May 14, 2026 Referred to the House Committee on Energy and Commerce.
- May 14, 2026 Submitted in House
Votes
No recorded votes are available for this bill.